Organogenesis Holdings Inc. (ORGO)

2,3900 -0,1000 (-4,02%) Alla chiusura: 04:00PM EDT

Organogenesis Holdings Inc.

85 Dan Road
Canton, MA 02021
United States
781 575 0775
https://organogenesis.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 862

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Gary S. Gillheeney Sr.	President, CEO, Chair of the Board	1,75M	N/D	1955
Mr. David C. Francisco	Chief Financial Officer	628,52k	N/D	1966
Mr. Patrick Bilbo	Chief Operating Officer	806,49k	N/D	1962
Ms. Lori H. Freedman B.A., Esq., J.D.	Chief Administrative & Legal Officer	844,26k	N/D	1967
Mr. Brian Grow	Chief Commercial Officer	724,12k	N/D	1977
Mr. William R. Kolb CPA	Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Organogenesis Holdings Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.